Drug Profile
Research programme: immune-modulatory therapeutics - Boehringer Ingelheim/Yale University
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Yale University
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Respiration disorders
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Feb 2019 No recent reports of development identified for research development in Cancer in USA
- 28 Feb 2019 No recent reports of development identified for research development in Respiration-disorders in USA